Recipharm completes acquisition of Flamel Technologies facility in France

The contract development and manufacturing organisation, Recipharm AB has today
completed the purchase of the Flamel Technologies SA facility located in Pessac,
France.
Thomas Eldered, CEO of Recipharm commented: “I am very happy that we have been
able to transfer ownership of Pessac this quickly after only signing the
agreement a few days ago. In the 4th quarter, we shall consolidate into our
accounts the Corvette acquisition from 1st of October, Lusomedicamenta from of
1st of November and now Pessac from 1st of December. The focus will now be to
integrate these acquisitions successfully into Recipharm and maximize benefit
from the business opportunities they create.”

For further information please visit www.recipharm.com or contact:
Thomas Eldered, CEO, Thomas.eldered@recipharm.com, +46 8 602 52 10
Björn Westberg, CFO, bjorn.westberg@recipharm.com, +46 8 602 46 20

This information is published in accordance with the Swedish Securities Market
Act, the Swedish Financial Instruments Trading Act and/or the regulations of
NASDAQ Stockholm. This information was submitted for publication on 1 December,
2014, at 18:00 hrs CET.

About Recipharm
Recipharm is a leading CDMO (Contract Development and Manufacturing
Organisation) in the pharmaceutical industry based in Sweden employing some
2,100 employees. Recipharm offers manufacturing services of pharmaceuticals in
various dosage forms, production of clinical trial material including API and
pharmaceutical product development. Recipharm manufactures more than 400
different products to customers ranging from Big Pharma through to smaller
research- and development companies. Recipharm’s turnover is approximately SEK
3.2 billion and the Company operates development and manufacturing facilities in
Sweden, France, the UK, Germany, Spain, Italy and Portugal and is headquartered
in Jordbro, Sweden. The Recipharm B-share (RECI B) is listed on NASDAQ
Stockholm.

For more information on Recipharm and our services, please visit
www.recipharm.com (http://file///C:/Users/Thomas/AppData/Local/Microsoft/Windows
/ 
Temporary%20Internet%20Files/Content.Outlook/FZHEQOEB/visit%20www.recipharm.com)
. 


Recipharm has retained Ramboult-Legoater and Obermayer Rebmann Maxwell & Hippel
LLP as advisors in this transaction.
Recipharm AB (publ)
Corporate identity number 556498-8425
Address Lagervägen 7, SE-136 50 Jordbro, Sweden Telephone 46 8 602 52 00, Fax 46
8 81 87 03
www.recipharm.com